M. Bjursell

Understanding the patient experience of chronic kidney disease stages 2–3b: a qualitative interview study with Kidney Disease Quality of Life (KDQOL-36) debrief

A. Rydén, S. Nolan, Oren Meyers, 2022, BMC Nephrology.

Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia

R. Terkeltaub, V. Perkovic, H. Heerspink, 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX.

M. Roe, Jie-Lena Sun, A. Carnicelli, 2020, The American journal of medicine.

Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout.

Neha J. Pagidipati, M. Roe, N. Pagidipati, 2020, The American journal of cardiology.

Verinurad does not prolong QTc interval: a thorough QT study using concentration–QTc modelling

C. Gottfridsson, J. Parkinson, C. Dota, 2022, British Journal of Clinical Pharmacology.

Urate‐lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink

M. Bjursell, S. Perl, S. Kiddle, 2024, Clinical cardiology.